Leqvio

Active Ingredient(s): Inclisiran
FDA Approved: * December 22, 2021
Pharm Company: * NOVARTIS PHARMS CORP
Category: Heart (Cardiac)

Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.[5][6][7][2] Inclisiran was approved for use in the European Union in December 2020.[4] In August 2021, it received NIC... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Leqvio 284 mg/1.5ml Subcutaneous Injection, Solution
NDC: 0078-1000
Labeler:
Novartis Pharmaceuticals Corporation